CYP3A4诱导与抑制对健康受试者SHR0302药代动力学的影响
SHR0302主要经CYP3A4代谢。两项I期开放标签固定序列药物相互作用研究共纳入28名健康受试者,分别评估利福平(强诱导剂)和伊曲康唑(强抑制剂)对SHR0302药代动力学的影响。结果显示利福平使SHR0302的AUC0-inf几何均值比降至0.51,伊曲康唑使其升至1.48,但Cmax变化较小,总体影响为弱效应。
要点
- 利福平使SHR0302的AUC0-inf几何均值比降至0.51(90%CI 0.49, 0.54)。
- 伊曲康唑使SHR0302的AUC0-inf几何均值比升至1.48(90%CI 1.41, 1.56)。
- 强CYP3A4诱导或抑制对SHR0302临床暴露的影响均为弱效应。
核心结论
- 强CYP3A4诱导和抑制对SHR0302的临床暴露均产生弱效应。
研究设计与样本
- 两项I期、开放标签、固定序列药物相互作用研究,共纳入28名健康受试者。
- 研究A中14名受试者第1天和第10天接受8 mg SHR0302,第3-11天每日一次接受600 mg利福平。
- 研究B中14名受试者第1天和第8天接受4 mg SHR0302,第4-10天每日一次接受200 mg伊曲康唑。
主要发现
- 合用利福平后,SHR0302的AUC0-inf几何均值比(90%CI)为0.51(0.49, 0.54),Cmax几何均值比为0.91(0.84, 0.98)。
- 合用伊曲康唑后,SHR0302的AUC0-inf几何均值比(90%CI)为1.48(1.41, 1.56),Cmax几何均值比为1.06(0.982, 1.14)。
- 单次口服SHR0302联用或不联用利福平或伊曲康唑总体安全。
关键数值与推荐
- 利福平使SHR0302的AUC0-inf几何均值比降至0.51(90%CI 0.49, 0.54)。
- 伊曲康唑使SHR0302的AUC0-inf几何均值比升至1.48(90%CI 1.41, 1.56)。
临床怎么用
- 研究结果为SHR0302的给药说明和合并用药注意事项提供了参考信息。
局限性
- 研究仅纳入健康受试者,未涉及患者人群。
- 研究样本量较小(共28名受试者)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: SHR0302 is a selective Janus kinase (JAK) 1 inhibitor under clinical investigation for the treatment of rheumatoid arthritis (RA). As SHR0302 is metabolized mainly by cytochrome P450 (CYP) 3A4, clinical studies were performed to evaluate the effects of a strong CYP3A4 inducer, rifampin, and a strong CYP3A4 inhibitor, itraconazole, on the pharmacokinetics of SHR0302 in healthy subjects. METHODS: Two phase I, open-label, fixed-sequence drug interaction studies enrolled 28 subjects. In Study A, 14 subjects received 8 mg SHR0302 on Days 1 and 10, and 600 mg rifampin once daily on Days 3-11. In Study B, 14 subjects received 4 mg SHR0302 on Days 1 and 8, and 200 mg itraconazole once daily on Days 4-10. Blood samples were collected to measure SHR0302 concentrations. Pharmacokinetic parameters were calculated using non-compartmental analysis. Treatment comparisons were made using mixed-effect models. RESULTS: Co-administration with rifampin decreased the exposures of SHR0302 with geometric mean ratios (GMRs) (90% confidence intervals [CIs]) for AUC0-inf of 0.51 (0.49, 0.54) and Cmax of 0.91 (0.84, 0.98). Co-administration with itraconazole increased the exposures of SHR0302 with GMR (90% CIs) for AUC0-inf of 1.48 (1.41, 1.56) and Cmax of 1.06 (0.982, 1.14). Single oral doses of SHR0302 administered with or without rifampin or itraconazole were generally safe. CONCLUSIONS: Strong CYP3A4 induction and inhibition both resulted in a weak effect on the clinical exposures of SHR0302. These present studies provided valuable information that helps inform SHR0302 dosing instructions and concomitant medication precautions.
引用
- Zhang Z, Gao X, Zhang P, et al. Effect of CYP3A4 induction and inhibition on the pharmacokinetics of SHR0302 in healthy subjects. Br J Clin Pharmacol. 2023. PMID: 37005376. doi:10.1111/bcp.15733
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。